Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should ...
Kyowa Kirin will now file for rocatinlimab’s US approval in atopic dermatitis (AD), which was once Amgen’s most late-stage pipeline candidate.
Product is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE ...
India's pharmaceutical and biopharmaceutical industry has welcomed the Union Budget 2026, particularly the launch of the ...
As this complexity deepens, a simple truth emerges: classical measurement frameworks cannot keep pace with a system that is no longer linear, nor even merely non-linear, but fundamentally ...
Congressional appropriations package expands reporting obligations for PBMs to increase transparency. It also delinks PBM ...
(Nasdaq: SPRC) ("Company” or "SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...
“The topline results from Ascletis’ Phase 3 open-label acne trial in China build additional confidence in the clinical potential of FASN inhibition in acne,” said David Happel, Chief Executive Officer ...
3hon MSN
Hedge funds trim North America exposure amid trade tensions, dollar pain and megacap weakness
By Anirban Sen NEW YORK, Feb 2 (Reuters) - Hedge funds have been diversifying their allocations away from North America over ...
The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its fifth and biggest fund to date.
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results